ReviewFrontiers in surgery2026
Oncologic standards in colon cancer resection: from margins to lymph node yield and mesentery.
Review in Frontiers in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oncologic quality in colon cancer surgery hinges on achieving adequate longitudinal margins, lymphadenectomy, and mesenteric excision, yet international standards and segment-specific practices remain heterogeneous. Methods: A focused PubMed/MEDLINE search from inception to October 2025 identified international guidelines, randomized and non-randomized comparative studies, large registries, and meta-analyses addressing: (1) longitudinal resection margins; (2) lymph node (LN) yield and nodal metrics; and (3) complete mesocolic excision (CME) with central vascular ligation (CVL)/D3 versus standard colectomy in curative-intent colon cancer surgery. The study aimed to delineate current standards in colon cancer resection. Results: Mapping studies and guidelines converge on 5-7 cm longitudinal margins for most tumors, with extension toward 10 cm in advanced T stage (cT3-cT4 disease) or when arterial geometry indicates a longer at-risk pericolic segment. LN assessment beyond the historical ≥12 minimum improves staging accuracy and survival, with several large datasets suggesting a plateau around 18-22 examined nodes. CME/CVL/D3 reliably increases nodal yield and specimen quality without excess morbidity in optimized settings and appears to confer an oncologic advantage across stages II-III, with the most consistent survival signal in stage III disease. Conclusion: An oncologically adequate colectomy should aim for: (1) R0 resection with 5-7 cm margins, extendable toward 10 cm when dictated by tumor stage or vascular anatomy; (2) mesenteric resection to the feeding-vessel origin targeting 18-22 LNs (minimum ≥12), with systematic reporting of tumor deposits and LN ratio; and (3) thoughtful use of CME/CVL/D3 embedded within structured training and routine audit of outcomes, particularly for stage III right colon cancers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.